Advertisement

Ovarian Cancer Relapse: Experimental Therapies

  • Melina Shoni
  • Ursula A. MatulonisEmail author
Chapter

Abstract

Epithe ovarian cancer has the highest mortality of all gynecologic cancers with an estimated 22,280 cases diagnosed in 2012 in the United States and 15,500 deaths [1]. For women between the ages of 60 and 79 years of age, ovarian cancer is the fifth leading cause of cancer death following lung, breast, colorectal, and pancreatic cancer [2]. Survival improvements for newly diagnosed ovarian cancer have reached a plateau using upfront surgery followed by platinum- and taxane-based chemotherapy. Thus, investigational efforts with new therapeutic agents are underway in an effort to overcome platinum- and chemotherapy-resistant cancer and ultimately improve survival. Insights into the molecular biology of ovarian cancer through mechanisms such as The Cancer Genome Atlas Project have identified potential therapeutic targets [2]. Efficacy, toxicities, and drug metabolism related to targeted therapies in the elderly patient with ovarian cancer are not available, and thus, data on the risk-benefit ratio of targeted therapies in this age group are mainly derived from studies in non-gynecologic cancers. This chapter reviews the available targeted therapies for the management of ovarian cancer and outlines the application of newer biologic agents in elderly patients with recurrent ovarian cancer.

Keywords

Ovarian cancer Elderly Targeted therapies Relapse Management 

Abbreviations

HTN

Hypertension

RF

Renal failure

FDA

Food and Drug Administration

ATE

Arterial thromboembolic event

VTE

Venous thromboembolic event

GIP

Gastrointestinal perforation

TKI

Tyrosine kinase inhibitor

IV

Intravenous

PFS

Progression-free survival

OS

Overall survival

PLD

Pegylated liposomal doxorubicin

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62(1): 10–29.PubMedGoogle Scholar
  2. 2.
    Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.Google Scholar
  3. 3.
    Gloeckler LA. Ovarian cancer: survival and treatment differences by age. Cancer. 1993;71:524–9.Google Scholar
  4. 4.
    Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71(2 Suppl):606–14. Epub 1993/01/15.PubMedGoogle Scholar
  5. 5.
    Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data. Am J Obstet Gynecol. 1986;154(3):639–47. Epub 1986/03/01.PubMedGoogle Scholar
  6. 6.
    Markman M, Lewis Jr JL, Saigo P, Hakes T, Rubin S, Jones W, et al. Impact of age on survival of patients with ovarian cancer. Gynecol Oncol. 1993;49(2):236–9. Epub 1993/05/01.PubMedGoogle Scholar
  7. 7.
    Riggs JE. Rising ovarian cancer mortality in the elderly: a manifestation of differential survival. Gynecol Oncol. 1995;58(1):64–7. Epub 1995/07/01.PubMedGoogle Scholar
  8. 8.
    Susini T, Scambia G, Margariti PA, et al. Gynecologic oncology surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol. 1999;75:437–43.PubMedGoogle Scholar
  9. 9.
    Eisenhauer EL, Tew WP, Levine DA, et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007;106:381–7.PubMedGoogle Scholar
  10. 10.
    Repetto L, Venturino A, Vercelli M, Gianni W, Biancardi V, Casella C, et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer. 1998;82(4):760–5. Epub 1998/02/26.PubMedGoogle Scholar
  11. 11.
    Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol. 2007;25(14):1858–69. Epub 2007/05/10.PubMedGoogle Scholar
  12. 12.
    Pignata S, Vermorken JB. Ovarian cancer in the elderly. Crit Rev Oncol Hematol. 2004;49(1):77–86. Epub 2004/01/22.PubMedGoogle Scholar
  13. 13.
    Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol. 2003;102(1):156–61. Epub 2003/07/10.PubMedGoogle Scholar
  14. 14.
    Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen-Heijnen ML. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol. 2005;97(1):104–9. Epub 2005/03/26.PubMedGoogle Scholar
  15. 15.
    Tetsche MS, Norgaard M, Jacobsen J, Wogelius P, Sorensen HT. Comorbidity and ovarian cancer survival in Denmark, 1995–2005: a population-based cohort study. Int J Gynecol Cancer. 2008;18(3):421–7. Epub 2007/08/19.PubMedGoogle Scholar
  16. 16.
    Diaz-Montes TP, Zahurak ML, Giuntoli 2nd RL, Gardner GJ, Gordon TA, Armstrong DK, et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol. 2005;99(2):352–7. Epub 2005/08/02.PubMedGoogle Scholar
  17. 17.
    Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, et al. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol Oncol. 2009;112(2):394–9. Epub 2008/12/09.PubMedGoogle Scholar
  18. 18.
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit Rev Oncol Hematol. 2009;71(3):233–41. Epub 2009/01/31.PubMedGoogle Scholar
  19. 19.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. Epub 2011/03/08.PubMedGoogle Scholar
  20. 20.
    SEER. Surveillance, epidemiology and end results. http://seer.cancer.gov/statfacts/html/ovary.html. Accssed on Oct 15, 2012.
  21. 21.
    Freyer G, Tinker AV. Clinical trials and treatment of the elderly diagnosed with ovarian cancer. Int J Gynecol Cancer. 2011;21(4):776–81. Epub 2011/05/06.PubMedGoogle Scholar
  22. 22.
    Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23(13):3112–24. Epub 2005/04/30.PubMedGoogle Scholar
  23. 23.
    Hilpert F, Wimberger P, du Bois A, Pfisterer J, Harter P. Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience. Onkologie. 2012;35(3):76–81. Epub 2012/03/15.PubMedGoogle Scholar
  24. 24.
    Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626–31. Epub 2004/11/16.PubMedGoogle Scholar
  25. 25.
    Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383–9. Epub 2003/03/29.PubMedGoogle Scholar
  26. 26.
    Hutchins LF, Unger JM, Crowley JJ, Coltman Jr CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–7. Epub 1999/12/30.PubMedGoogle Scholar
  27. 27.
    Yee KW, Pater JL, Pho L, Zee B, Siu LL. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003;21(8):1618–23. Epub 2003/04/17.PubMedGoogle Scholar
  28. 28.
    Lara Jr PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728–33. Epub 2001/03/17.PubMedGoogle Scholar
  29. 29.
    Gonsalves W, Ganti AK. Targeted anti-cancer therapy in the elderly. Crit Rev Oncol Hematol. 2011;78(3):227–42. Epub 2010/07/06.PubMedGoogle Scholar
  30. 30.
    Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol. 2011;9(2):98–109. Epub 2011/12/21.PubMedGoogle Scholar
  31. 31.
    Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32(2):169–75. Epub 2007/03/27.PubMedGoogle Scholar
  32. 32.
    Townsley CA, Pond GR, Oza AM, Hirte HW, Winquist E, Goss G, et al. Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res. 2006;12(7 Pt 1):2141–9. an official journal of the American Association for Cancer Research. Epub 2006/04/13.PubMedGoogle Scholar
  33. 33.
    Schmitt J, Matei D. Targeting angiogenesis in ovarian cancer. Cancer Treat Rev. 2011;38(4):272–83. Epub 2011/07/19.PubMedGoogle Scholar
  34. 34.
    Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol. 2007;25(20):2894–901.PubMedGoogle Scholar
  35. 35.
    Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121(1):230–8. Epub 2011/01/11.PubMedGoogle Scholar
  36. 36.
    Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer. 2000;83(2):196–203. Epub 2000/07/20.PubMedGoogle Scholar
  37. 37.
    Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996;74(6):1105–15. Epub 1996/06/01.PubMedGoogle Scholar
  38. 38.
    Smerdel MP, Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol. 2010;118(2):167–71. Epub 2010/05/18.PubMedGoogle Scholar
  39. 39.
    Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193–7. Epub 2002/10/11.PubMedGoogle Scholar
  40. 40.
    Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512–7.PubMedGoogle Scholar
  41. 41.
    Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–9. Epub 1997/10/23.PubMedGoogle Scholar
  42. 42.
    Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165–71.PubMedGoogle Scholar
  43. 43.
    Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180–6.PubMedGoogle Scholar
  44. 44.
    Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26(1):76–82.PubMedGoogle Scholar
  45. 45.
    Rose PG, Drake R, Braly PS, et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol. 2009;27(suppl):Abstract 5546.Google Scholar
  46. 46.
    Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, et al. Safety, efficacy, and biomarker exploration in a phase II study of Bevacizumab, Oxaliplatin, and gemcitabine in recurrent Mullerian carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011;4(1):26–33. Epub 2011/08/13.PubMedGoogle Scholar
  47. 47.
    Tillmanns TD, Lowe MP, Schwartzberg LS, Walker MS, Stepansk EJ. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol. 2010;28(suppl):Abstract 5009.Google Scholar
  48. 48.
    Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28(1):154–9.PubMedGoogle Scholar
  49. 49.
    Lee JM, Sarosy GA, Annunziata CM, et al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer. 2010;102:495–9.PubMedGoogle Scholar
  50. 50.
    Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26:3709–14.PubMedGoogle Scholar
  51. 51.
    Nimeiri HS, Oza AM, Morgan RJ. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008;110(1):49–55.PubMedGoogle Scholar
  52. 52.
    Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.PubMedGoogle Scholar
  53. 53.
    Perren TJ, Swart AM, Pfisterer J, et al. A phase III trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.PubMedGoogle Scholar
  54. 54.
    Agency: EM. Avastin (bevacizumab) product page. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf Accessed on 15 Oct 2012.
  55. 55.
    Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blinded, ­placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.PubMedGoogle Scholar
  56. 56.
    Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. J Clin Oncol. 2012 ;30(suppl): Abstract LBA 5002.Google Scholar
  57. 57.
    Barni S, Cabiddu M, Petrelli F. Toxicity of targeted therapies in elderly patients. Expert Rev Anticancer Ther. 2008;8(12):1965–76. Epub 2008/12/03.PubMedGoogle Scholar
  58. 58.
    Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117(3):497–504. Epub 2010/04/07.PubMedGoogle Scholar
  59. 59.
    Avastin. [package insert]. South San Francisco: Genentech Inc; 2009.http://www.fda.gov.
  60. 60.
    Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9. Epub 2007/08/10.PubMedGoogle Scholar
  61. 61.
    Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14(9):862–70. Epub 2009/09/04.PubMedGoogle Scholar
  62. 62.
    Meyerhardt JA, Li L, Sanoff HK, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30(6):608–15.PubMedGoogle Scholar
  63. 63.
    Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26(1):60–5. Epub 2008/01/01.PubMedGoogle Scholar
  64. 64.
    Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J Clin Oncol. 2007;25(18S):276s. Abstract 5508.Google Scholar
  65. 65.
    Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13:154–62.PubMedGoogle Scholar
  66. 66.
    Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601–6.PubMedGoogle Scholar
  67. 67.
    Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011;29(1):69–75.PubMedGoogle Scholar
  68. 68.
    Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol. 2011;22(2):335–40.PubMedGoogle Scholar
  69. 69.
    Campos S, Penson RT, Berlin S, et al. A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian and peritoneal carcinoma. Gynecol Oncol. 2010;116(3 (suppl 1)):S119–20. Abstarct 306.Google Scholar
  70. 70.
    Baumann KH, du Bois A, Meier W, et al. A phase II trial (AGO 2.11. in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. 2012;23(9):2265–71.PubMedGoogle Scholar
  71. 71.
    Friedlander M, Hancock KC, Rischin D, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119:32–7.PubMedGoogle Scholar
  72. 72.
    Matulonis U, Tew WP, Matei D, et al. Phase II study of ENMD-2076 in platinum resistant ovarian cancer. J Clin Oncol. 2011;29(suppl):Abstract 5021.Google Scholar
  73. 73.
    Vergote I, Sella A, Bedell C, et al. Phase II study of XL184 in a cohort of ovarian cancer patients with measurable soft tissue disease [Abstract 407]. Proceedings of the 22nd EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics conference, Berlin, 2010.Google Scholar
  74. 74.
    Buckanovich RJ, Berger R, Sella A, et al. Activity of cabozantinib (XL184. in advanced ovarian cancer patients: results from a phase II randomized discontinuation trial. J Clin Oncol. 2011;29(suppl):Abstract 5008.Google Scholar
  75. 75.
    Santos ES, Gomez JE, Raez LE. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest New Drugs. 2012;30(3):1261–9.PubMedGoogle Scholar
  76. 76.
    Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):311–9. Epub 2009/12/24.PubMedGoogle Scholar
  77. 77.
    Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29:3798–804.PubMedGoogle Scholar
  78. 78.
    Coleman RL, Moon J, Sood A et al. Randomized phase II study of docetaxel plus vandetanib (D+V. versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: SWOG S0904. J Clin Oncol. 2012;30:Abstract 5015.Google Scholar
  79. 79.
    Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6(10):569–79.PubMedGoogle Scholar
  80. 80.
    Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6(5):507–16. Epub 2004/11/16.PubMedGoogle Scholar
  81. 81.
    Wu B, Johnson J, Soto M, Ponce M, Calamba D, Sun YN. Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models. Pharm Res. 2012;29(4):1057–65. Epub 2011/12/23.PubMedGoogle Scholar
  82. 82.
    Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo controlled, phase II study of AMG386 with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. J Clin Oncol. 2012;30(4):362–71.PubMedGoogle Scholar
  83. 83.
    Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl). 2006;84(8):671–81.Google Scholar
  84. 84.
    Sheng Q, Liu X, Fleming E, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010;17(3):298–310.PubMedGoogle Scholar
  85. 85.
    Zeineldin R, Muller CY, Stack MS, Hudson LG. Targeting the EGF receptor for ovarian cancer therapy. J Oncol. 2010;2010:414676. Epub 2010/01/13.PubMedGoogle Scholar
  86. 86.
    Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer. 2011;104(8):1241–5. Epub 2011/03/03.PubMedGoogle Scholar
  87. 87.
    Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer. 2005;15(5):785–92. Epub 2005/09/22.PubMedGoogle Scholar
  88. 88.
    Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11(15):5539–48. Epub 2005/08/03.PubMedGoogle Scholar
  89. 89.
    Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007;109(7):1323–30. Epub 2007/03/03.PubMedGoogle Scholar
  90. 90.
    Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283–90. Epub 2003/01/15.PubMedGoogle Scholar
  91. 91.
    Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24(26):4324–32. Epub 2006/08/10.PubMedGoogle Scholar
  92. 92.
    Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 2007;104(3):727–31. Epub 2006/11/28.PubMedGoogle Scholar
  93. 93.
    Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005;23(24):5597–604. Epub 2005/08/20.PubMedGoogle Scholar
  94. 94.
    Garcia AA, Sill MW, Lankes HA, et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;124:569–74.PubMedGoogle Scholar
  95. 95.
    Vasey PA, Gore M, Wilson R, Rustin G, Gabra H, Guastalla JP, et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer. 2008;98(11):1774–80. Epub 2008/05/29.PubMedGoogle Scholar
  96. 96.
    Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Luck HJ, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol. 2007;105(1):132–7. Epub 2006/12/13.PubMedGoogle Scholar
  97. 97.
    Mavroudis D, Efstathiou E, Polyzos A, et al. A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer. J Clin Oncol. 2004;22:14 [ASCO Meeting Abstracts] abstract 5020.Google Scholar
  98. 98.
    Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(3):493–9. Epub 2008/01/15.PubMedGoogle Scholar
  99. 99.
    Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol. 2010;119(3):451–6. Epub 2010/09/15.PubMedGoogle Scholar
  100. 100.
    Kimball KJ, Numnum TM, Kirby TO, Zamboni WC, Estes JM, Barnes MN, et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol. 2008;111(1):95–101.PubMedGoogle Scholar
  101. 101.
    Rivkin SE, Muller M, Iriarte D, Arthur J, Canoy A, Reid H. Phase I/II lapatinib plus ­carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients. J Clin Oncol. 2008;26:(suppl):Abstract 5556.Google Scholar
  102. 102.
    Hirte H, Oza A, Swenerton K, Ellard SL, Grimshaw R, Fisher B, et al. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol. 2010;118(3):308–12. Epub 2010/07/22.PubMedGoogle Scholar
  103. 103.
    Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010;28(7):1215–23. Epub 2009/11/11.PubMedGoogle Scholar
  104. 104.
    Kaye SB, Poole CJ, Bidzinksi L, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. J Clin Oncol. 2008;26(suppl):Abstract 5520.Google Scholar
  105. 105.
    Vergote IB, Joly F, Katsaros D, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC-GCG study. J Clin Oncol. 2012;30:Abstract LBA5000.Google Scholar
  106. 106.
    Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62. Epub 2009/07/25.PubMedGoogle Scholar
  107. 107.
    Bowtell DD. The genesis and evolution of high grade serous ovarian cancer. Nat Rev Cancer. 2010;10(11):803–8. Epub 2010 Oct 14.PubMedGoogle Scholar
  108. 108.
    Matulonis UA, Hirsch M, Palescandolo E, et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One. 2011;6(9):e24433. doi: 10.1371/journal.pone.0024433.PubMedGoogle Scholar
  109. 109.
    Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch. 2012;460(1):77–87.PubMedGoogle Scholar
  110. 110.
    Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;123(1):19–26. Epub 2011/07/15.PubMedGoogle Scholar
  111. 111.
    Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet. 2006;7(11):841–50. Epub 2006/10/19.PubMedGoogle Scholar
  112. 112.
    Blank U, Karlsson G, Karlsson S. Signaling pathways governing stem-cell fate. Blood. 2008;111(2):492–503. Epub 2007/10/05.PubMedGoogle Scholar
  113. 113.
    Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V, et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008;14(23):7659–66. Epub 2008/12/03.PubMedGoogle Scholar
  114. 114.
    McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One. 2011;6(11):e28077. Epub 2011/12/06.PubMedGoogle Scholar
  115. 115.
    Kaye S, Fehrenbacher L, Holloway R, et al. A phase 2, randomized, placebo-controlled study of Hedgehog Pathway Inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2nd or 3rd complete remission. Ann Oncol. 2010;21(suppl 8):Abstract LBA25.Google Scholar
  116. 116.
    Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci. 2006;11:506–19. Epub 2005/09/09.PubMedGoogle Scholar
  117. 117.
    Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619–26. Epub 2008/01/29.PubMedGoogle Scholar
  118. 118.
    Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74(2):193–8. Epub 1997/04/22.PubMedGoogle Scholar
  119. 119.
    Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16(21):5288–95. Epub 2010/09/22.PubMedGoogle Scholar
  120. 120.
    Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer. 2007;121(7):1585–92. Epub 2007/06/07.PubMedGoogle Scholar
  121. 121.
    Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol. 2009;49(12):1467–76. Epub 2009/10/20.PubMedGoogle Scholar
  122. 122.
    Naumann RW CR, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone in subjects with platinum-resistant ovarian cancer [abstract #5045]. In: Proceedings of the 2011 American Society of Clinical Oncology meeting, Chicago, 2011.Google Scholar
  123. 123.
    Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57(6):1116–23. Epub 1997/03/15.PubMedGoogle Scholar
  124. 124.
    Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer. 2009;45(8):1415–23. Epub 2009/01/27.PubMedGoogle Scholar
  125. 125.
    Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27(16):2686–91. Epub 2009/04/01.PubMedGoogle Scholar
  126. 126.
    Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761–6. Epub 2008/11/13.PubMedGoogle Scholar
  127. 127.
    Sehouli J, Alvarez AM, Manouchehrpour S, et al. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2012;124(2):205–9.PubMedGoogle Scholar
  128. 128.
    Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011;105(8):1114–22. Epub 2011/10/13.PubMedGoogle Scholar
  129. 129.
    Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293–301. Epub 2010/03/05.PubMedGoogle Scholar
  130. 130.
    Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864–74. Epub 2006/09/26.PubMedGoogle Scholar
  131. 131.
    McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15. Epub 2006/08/17.PubMedGoogle Scholar
  132. 132.
    Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–90.PubMedGoogle Scholar
  133. 133.
    Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7. Epub 2005/04/15.PubMedGoogle Scholar
  134. 134.
    Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.PubMedGoogle Scholar
  135. 135.
    Iglehart JD, Silver DP. Synthetic lethality – a new direction in cancer-drug development. N Engl J Med. 2009;361(2):189–91. Epub 2009/06/26.PubMedGoogle Scholar
  136. 136.
    Hennessy B, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP Ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570–6.PubMedGoogle Scholar
  137. 137.
    Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34. Epub 2009/06/26.PubMedGoogle Scholar
  138. 138.
    Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737): 245–51. Epub 2010/07/09.PubMedGoogle Scholar
  139. 139.
    Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–61. Epub 2011/08/25.PubMedGoogle Scholar
  140. 140.
    Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of Olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2011;30(4):372–9. Epub 2011/12/29.PubMedGoogle Scholar
  141. 141.
    Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15): 1382–92. Epub 2012/03/29.PubMedGoogle Scholar
  142. 142.
    Oza A, Cibula D, Oaknin A, et al. Olaparib plus paclitaxel plus carboplatin followed by olaparib maintenance treatment in patients with platinum sensitive recurrent serous ovarian cancer: a randomized, open-lable phase II study. J Clin Oncol. 2012;30:Abstract 5001.Google Scholar
  143. 143.
    Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106(3):468–74. Epub 2012/01/10.PubMedGoogle Scholar
  144. 144.
    Liu J, Fleming G, Tolaney SM, Birrer MJ, Penson RT, Berlin ST, et al. A phase I trial of the PARP inhibitor olaparib (AZD2281. in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. J Clin Oncol. 2011;29(suppl):Abstract 5028.Google Scholar
  145. 145.
    Keen N, Taylor S. Mitotic drivers – inhibitors of the Aurora B Kinase. Cancer Metastasis Rev. 2009;28(1–2):185–95. Epub 2009/02/04.PubMedGoogle Scholar
  146. 146.
    Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 2000;6(5):1833–9. Epub 2000/05/18.PubMedGoogle Scholar
  147. 147.
    Landen Jr CN, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, et al. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res. 2007;13(14):4098–104. Epub 2007/07/20.PubMedGoogle Scholar
  148. 148.
    Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, et al. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008;14(17):5437–46. Epub 2008/09/04.PubMedGoogle Scholar
  149. 149.
    Matulonis U, Sharma SK, Ghamande S, et al. Single-agent activity and safety of the investigational aurora A kinase inhibitor MLN8237 in patients with platinum-treated epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Ann Oncol (Meet Abstr). 2010;21(suppl 8):974PD.Google Scholar
  150. 150.
    Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell. 2003;3(1):51–62.PubMedGoogle Scholar
  151. 151.
    Yang H, He L, Kruk P, et al. Aurora A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006;119(10): 2304–12.PubMedGoogle Scholar
  152. 152.
    Scharer CD, Laycock N, Osunkoya AO, et al. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med. 2008;6:79.PubMedGoogle Scholar
  153. 153.
    Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13.PubMedGoogle Scholar
  154. 154.
    Kandalaft LE, Powell DJ, Singh N, et al. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol. 2011;29(7):925–33.PubMedGoogle Scholar
  155. 155.
    Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol. 2010;3:7. Epub 2010/02/12.PubMedGoogle Scholar
  156. 156.
    Sabbatini P, Spriggs D, Aghajanian C, Hensley M, Tew W, Konner J, et al. Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecol Oncol. 2010;116(1):66–71. Epub 2009/10/20.PubMedGoogle Scholar
  157. 157.
    Pfisterer J, Berek JS, Casado K, et al. Randomized double-blind placebo-controlled international trial of abagovomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: the monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous Abagovomab (MIMOSA. trial). J Clin Oncol. 2011;29(suppl):Abstract LBA5002.Google Scholar
  158. 158.
    Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008;105(8):3005–10.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of Medical OncologyDana-Farber Cancer InstituteBostonUSA

Personalised recommendations